



Visit **cvs.co/ai-list** or scan the QR code to view electronically. For easy access, you can bookmark this page.

Autoimmune (AI) Drug List

Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Actemra (tocilizumab)	Genentech	 CRS (2+) GCA PJIA (2+) RA SJIA (2+) SSc-ILD Hospitalized adults who have COVID-19 	 SC injection: Self-administered IV infusion: Prepared and infused by a health care professional 	SC: • 162 mg/0.9 mL PFS • 162 mg/0.9 mL PEN IV: • 80 mg/4 mL • 200 mg/10 mL • 400 mg/20 mL	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in original packages Protect from light Keep syringes dry 	Upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased alanine aminotransferase (ALT) and injection site reactions
Adalimumab-aacf (unbranded version of Idacio)	Fresenius Kabi	 AS CD (6+) HS (12+) PJIA (2+) PsA PsO RA UC UV 	SC injection: • Self-administered	SC: • 40 mg/0.8 mL PEN • 40 mg/0.8 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in original packages Protect from light 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Adalimumab-aaty (unbranded version of Yuflyma)	Celltrion USA	SC injection: • AS • CD (6+) • HS • PJIA (2+) • PsA • PsO • RA • UC • UV	SC injection: • Self-administered	SC: • 40 mg/0.4 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in original packages Protect from light 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Adalimumab-adaz (unbranded version of Hyrimoz)	Sandoz	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	SC: • 10 mg/0.1 mL PFS • 20 mg/0.2 mL PFS • 40 mg/0.4 mL PFS • 40 mg/0.4 mL PEN • 80 mg/0.8 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in original packages Protect from light 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Adalimumab-fkjp (unbranded version of Hulio)	Mylan	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	 SC: 40 mg/0.8 mL PEN 40 mg/0.8 mL PFS 20 mg/0.4 mL PFS 	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original package 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Adbry (tralokinumab-ldrm)	LEO Pharma	• AD (12+)	SC injection: • Self-administered	SC: • 150 mg/mL PFS • 300 mg/2 mL PEN	 Store refrigerated at 36°F to 46°F (2°C to 8°C) Store in the original carton to protect from light 	Upper respiratory tract infections, conjunctivitis, injection site reactions and eosinophilia



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Amjevita (adalimumab-atto)	Amgen	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	SC: • 80 mg/0.8 mL PEN • 40 mg/0.4 mL PEN • 40 mg/0.4 mL PFS • 20 mg/0.2 mL PFS • 10 mg/0.2 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original package 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Arcalyst (rilonacept)	Kiniksa Pharmaceuticals	 CAPS (12+) FCAS (12+) MWS (12+) DIRA (≥10 kg) RP (12+) 	SC injection: • Self-administered	SC: • 220 mg of lyophilized powder in a single dose vial for reconstitution	 Refrigerate at 36°F to 46°F (2°C to 8°C) Store in original carton Protect from light Do not use beyond the date stamped on the label After reconstitution, may be kept at room temperature, protected from light 	Injection-site reactions and upper respiratory tract infections



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Avsola (infliximab-axxq)	Amgen	 AS CD (6+) PsO PsA RA UC (6+) 	 IV infusion: Prepared and infused by a health care professional 	IV: • 100 mg lyophilized powder in a single dose vial for reconstitution	 Store unopened Avsola vials in a refrigerator at 36°F to 46°F (2°C to 8°C) Protect from light 	Infections (e.g., upper respiratory, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain
Benlysta (belimumab)	GlaxoSmithKline	• SLE (5+) • LN (5+)	 IV infusion: Prepared and infused by a health care professional SC injection: Self-administered 	 IV: 120 mg lyophilized powder in a single dose vial for reconstitution 400 mg lyophilized powder in a single dose vial for reconstitution SC: 200 mg/mL PEN 200 mg/mL PFS 	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in original packages Protect from light Avoid exposure to heat 	Nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, pharyngitis, insomnia, pain in extremity, depression and migraine
Bimzelx (bimekizumab-bkzx)	UCB	 AS HS Nr-axSPA PsO PsA 	SC injection: • Self-administered	SC: • 160mg/mL PEN • 160mg/mL PFS • 320 mg/2 mL PEN • 320 mg/2 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Do not shake Store in original carton to protect from light 	Upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes simplex infections, acne, folliculitis, other candida infections and fatigue



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Cibinqo (abrocitinib)	Pfizer	• AD (12+)	Oral	Oral: • 50 mg tablets • 100 mg tablets • 200 mg tablets	 Store at 68°F to 77°F (20°C to 25°C) Keep in original package 	Nasopharyngitis, nausea, headache, herpes simplex, increased blood creatinine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, oropharyngeal pain, influenza, gastroenteritis, impetigo, hypertension, contact dermatitis, upper abdominal pain, abdominal discomfort, herpes zoster and thrombocytopenia
Cimzia (certolizumab pegol)	UCB	 AS CD Nr-axSpA PJIA (2+) PsO PsA RA 	SC injection: • Self-administered (PFS only)	SC: • 200 mg/mL PFS • 200 mg lyophilized powder in a single- dose vial (for health care professional use only)	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light 	Upper respiratory tract infection, rash and urinary tract infection
Cosentyx (secukinumab)	Novartis	SC: • AS • ERA (4+) • HS • Nr-axSpA • PsO (6+) • PsA (2+)	SC injection: • Self-administered	SC: • 75 mg/0.5 mL PFS • 150 mg/mL PEN • 150 mg/mL PFS • 300 mg/2 mL PEN • 300 mg/2 mL PFS	 SC: Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Keep the product in the original carton Protect from light Do not shake to avoid foaming 	Nasopharyngitis, diarrhea and upper respiratory tract infection



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Dupixent (dupilumab)	Sanofi	 AD (6 mo+) Asthma (6+) COPD CRSwNP (12+) CRSwNP EoE (1+ and ≥ 15 kg) PN 	SC injection: • Self-administered	SC: • 100 mg/0.67 mL PFS • 200 mg/1.14 mL PEN • 200 mg/1.14 mL PFS • 300 mg/2 mL PEN • 300 mg/2 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light Do not freeze 	Injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection and dry eye
Ebglyss (lebrikizumab-lbkz)	Eli Lilly	• AD (12+)	SC injection: • Self-administered	SC: • 250 mg/2 mL PFS • 250 mg/2 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) Store in the original carton to protect from light Do not freeze Do not shake 	Conjunctivitis, injection site reactions, and herpes zoster



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Enbrel (etanercept)	Amgen	• AS • JPsA (2+) • PsO (4+) • PsA (2+) • RA	SC injection: • Self-administered	 SC: 25 mg/0.5 mL single dose vial 25 mg lyophilized powder in a multiple dose vial for reconstitution 25 mg/0.5 mL PFS 50 mg/mL PFS 50 mg/mL PFS 50 mg/mL Enbrel Mini single-dose prefilled cartridge 	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Do not shake Store in the original carton to protect from light or physical damage 	Infections and injection site reactions
Entyvio (vedolizumab)	Takeda	• CD • UC	 IV infusion: Administered by a healthcare provider SC injection: Self-administered 	IV: • 300 mg single dose vial SC: • 108 mg/0.68 mL PEN	 Refrigerate unopened vials, PEN, and PFS at 36°F to 46°F (2°C to 8°C) Do not freeze Retain in original package to protect from light 	Nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain and pain in extremities. In addition, injection site reactions are associated with the SC injection only.



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Hadlima (adalimumab-bwwd)	Samsung Bioepis/ Organon	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	SC: • 40 mg/0.8 mL PFS • 40 mg/0.4 mL PFS • 40 mg/0.8 mL PEN • 40 mg/0.4 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original container 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Hulio (adalimumab-fkjp)	Mylan	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	 SC: 40 mg/0.8 mL PEN 40 mg/0.8 mL PFS 20 mg/0.4 mL PFS 	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original carton 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Humira (adalimumab)	AbbVie/ Cordavis	 AS CD (6+) HS (12+) PJIA (2+) PsO PsA RA UC (5+) UV (2+) 	SC injection: • Self-administered	SC: • 80 mg/0.8 mL PEN • 40 mg/0.8 mL PEN • 40 mg/0.4 mL PFS • 40 mg/0.8 mL PFS • 40 mg/0.4 mL PFS • 20 mg/0.2 mL PFS • 10 mg/0.1 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original carton 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Hyrimoz (adalimumab-adaz)	Cordavis/ Sandoz	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	SC: • 80 mg/0.8 mL PEN • 40 mg/0.4 mL PEN • 40 mg/0.8 mL PFS • 40 mg/0.8 mL PFS • 20 mg/0.2 mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original carton 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Idacio (adalimumab-aacf)	Fresenius Kabi	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	 SC: 40 mg/0.8 mL PEN 40 mg/0.8 mL PFS 	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Ilaris (canakinumab)	Novartis	 CAPS (4+) FCAS (4+) FMF Gout flares HIDS/MKD MWS (4+) TRAPS Active Still's Disease/ AOSD (2+) SJIA (2+) 	SC injection: • Should only be administered by a health care professional	SC: • 150 mg/mL single dose vial	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in the original carton to protect from light 	CAPS: Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, weight increased, musculoskeletal pain and vertigo TRAPS, HIDS/MKD, and FMF: injection-site reactions and nasopharyngitis Still's Disease: Nasopharyngitis and upper respiratory tract infections, abdominal pain and injection-site reactions Gout Flares: Nasopharyngitis, upper respiratory tract infections, urinary tract infections, hypertriglyceridemia and back pain



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Ilumya (tildrakizumab-asmn)	Sun Pharma	PsO	 SC injection: Should only be administered by a health care provider 	SC: • 100 mg/mL PFS	 Refrigerate at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light until the time of use Do not freeze Do not shake 	Upper respiratory infections, injection site reactions and diarrhea
Inflectra (infliximab-dyyb)	Celltrion/Pfizer	 AS CD (6+) PsO PsA RA UC (6+) 	 IV infusion: Prepared and infused by a health care professional 	 IV: 100 mg lyophilized in a powder single dose vial for reconstitution 	Refrigerate at 36°F to 46°F (2°C to 8°C)	Infections (e.g., upper respiratory, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain
Infliximab (unbranded version of Remicade)	Janssen	 AS CD (6+) PsO PsA RA UC (6+) 	 IV infusion: Prepared and infused by a health care professional 	 IV: 100 mg lyophilized in a powder single dose vial for reconstitution 	Refrigerate at 36°F to 46°F (2°C to 8°C)	Infections (e.g., upper respiratory, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain
Kevzara (sarilumab)	Sanofi	• RA • PJIA (> 63 kg) • PMR	SC injection: • Self-administered	SC: • 150 mg/1.14 mL PFS • 200 mg/1.14 mL PFS • 150 mg/1.14 mL PEN • 200 mg/1.14 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) in original carton to protect from light Do not freeze Do not shake 	RA: Neutropenia, increased ALT, injection site erythema, upper respiratory infections and urinary tract infections PMR: neutropenia, leukopenia and injection site pruritus



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Litfulo (ritlecitinib)	Pfizer	• AA (12+)	Oral	Oral: • 50 mg capsules	 Store at 68°F to 77°F (20°C to 25°C) Store in original package 	Headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, blood creatine phosphokinase increased, herpes zoster, red blood cell count decreased and stomatitis
Nemluvio (nemolizumab-ilto)	Galderma	• AD (12+) • PN	SC injection: • Self-administered	SC: • 30 mg/0.49 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) in original carton to protect from light Do not freeze 	Headache (including migraine), arthralgia, urticaria, and myalgia.



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Olumiant (baricitinib)	Eli Lilly	 AA RA Hospitalized adults who have COVID-19 	Oral	Oral: • 1 mg tablets • 2 mg tablets • 4 mg tablets	• Store at 68°F to 77°F (20°C to 25°C)	 RA: upper respiratory tract infections, nausea, herpes simplex and herpes zoster COVID-19: increases of liver enzymes, thrombocytosis, creatine phosphokinase increases, neutropenia, deep vein thrombosis, pulmonary embolism and urinary tract infection AA: upper respiratory tract infections, headache, acne, hyperlipidemia, creatine phosphokinase increase, urinary tract infection, liver enzyme elevations, folliculitis, fatigue, lower respiratory tract infections, nausea, genital Candida infections, anemia, neutropenia, abdominal pain, herpes zoster and weight increase
Omvoh (mirikizumab-mrkz)	Eli Lilly	• UC	 IV infusion: Infused by a health care professional SC injection: Self-administered 	IV: • 300 mg/15 mL single dose vial SC: • 100 mg/mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) Store in original container to protect from light Do not shake Do not freeze 	Induction: upper respiratory tract infections and arthralgia. Maintenance: upper respiratory tract infections, injection site reactions, arthralgia, rash, headache and herpes viral infection



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Orencia (abatacept)	Bristol Myers Squibb	IV: • PJIA (6+) • Prophylaxis of aGVHD (2+) • PsA • RA SC: • PJIA (2+) • PsA (2+) • RA	 IV infusion: Prepared and infused by a health care professional SC injection: Self-administered 	 IV: 250 mg lyophilized powder in a single dose vial for reconstitution SC: 50 mg/0.4 mL PFS 87.5 mg/0.7 mL PFS 125 mg/mL PFS 125 mg/mL PEN 	 IV: Refrigerate at 36°F to 46°F (2°C to 8°C) Store in original container Protect from light SC: Refrigerate at 36°F to 46°F (2°C to 8°C) Store in original container Protect from light Do not freeze 	IV: RA: headache, upper respiratory tract infection, nasopharyngitis and nausea aGVHD: anemia, hypertension, CMV reactivation/CMV infection, pyrexia, pneumonia, epistaxis, CD4 lymphocytes decreased, hypermagnesemia and acute kidney injury SC: Headache, upper respiratory tract infection, nasopharyngitis and nausea
Otezla (apremilast)	Amgen	 Oral ulcers associated with Behçet's Disease PsA PsO (6+) 	Oral	 Oral: 28 day Starter Pack: 10 mg, 20 mg, and 30 mg tablets 20 mg tablets 30 mg tablets 	• Store below 86°F (30°C)	 PsA: diarrhea, nausea and headache PsO: diarrhea, nausea, upper respiratory tract infection and headache, including tension headache Behçet's Disease: diarrhea, nausea, headache and upper respiratory tract infection



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Otrexup (methotrexate)	Antares Phar- ma/Otter Pharmaceuticals	• PJIA • PsO • RA	SC injection: • Self-administered	SC: • 10 mg/0.4 mL PEN • 12.5 mg/0.4 mL PEN • 15 mg/0.4 mL PEN • 17.5 mg/0.4 mL PEN • 20 mg/0.4 mL PEN • 22.5 mg/0.4 mL PEN • 25 mg/0.4 mL PEN	 Store at controlled room temperature, 77°F (25°C); excursions permitted to 59°F to 86°F (15°C to 30°C) Protect from light 	Nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leucopenia, pancytopenia, dizziness, photosensitivity and "burning of skin lesions"



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Rasuvo (methotrexate)	Medexus	• PJIA • PsO • RA	SC injection: • Self-administered	SC: • 7.5 mg/0.15 mL PEN • 10 mg/0.20 mL PEN • 12.5 mg/0.25 mL PEN • 15 mg/0.30 mL PEN • 17.5 mg/0.35 mL PEN • 20 mg/0.40 mL PEN • 22.5mg/0.45mL PEN • 25 mg/0.50 mL PEN • 27.5 mg/0.55 mL PEN • 30 mg/0.60 mL	 Store at controlled room temperature, 77°F (25°C) Protect from light 	Nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leucopenia, pancytopenia, dizziness, photosensitivity and "burning of skin lesions"
Remicade (infliximab)	Janssen	 AS CD (6+) PsO PsA RA UC (6+) 	 IV infusion: Prepared and infused by a health care professional 	IV: • 100 mg lyophilized powder in a single dose vial for reconstitution	 Refrigerate at 36°F to 46°F (2°C to 8°C) 	Infections (e.g., upper respiratory, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Renflexis (infliximab-abda)	Samsung Bioepsis/ Organon	 AS CD (6+) PsO PsA RA UC (6+) 	 IV infusion: Prepared and infused by a health care professional 	IV: • 100 mg lyophilized powder in a single dose vial for reconstitution	 Refrigerate at 36°F to 46°F (2°C to 8°C) 	Infections (e.g., upper respiratory, sinusitis and pharyngitis), infusion-related reactions, headache and abdominal pain
Riabni (rituximab-arrx)	Amgen	• RA	 IV infusion only: Administer only by a health care professional Do not administer by IV push or bolus 	 IV: 100 mg/10 mL single dose vial 500 mg/50 mL single dose vial 	 Refrigerate vials at 36°F to 46°F (2°C to 8°C) Do not freeze or shake Protect from direct sunlight 	Upper respiratory tract infection, nasopharyngitis, urinary tract infection and bronchitis (other important adverse reactions include infusion-related reactions, serious infections and cardiovascular events)



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Rinvoq (upadacitinib)	AbbVie	 AD (12+) AS CD Nr-axSpA PsA RA UC 	Oral	Oral: • Extended-release tablets: 15 mg, 30 mg, 45 mg Oral Solution (LQ): • 1 mg/1 mL only approved for PJIA (2+) and PsA (2+)	 Store at 36°F to 77°F (2°C to 25°C) Store in the original bottle to protect from moisture 	 RA/PsA/AS/nr-axSpA: upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne and headache AD: upper respiratory tract infections, acne, herpes simplex, headache, blood creatine phosphokinase increased, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia and influenza like illness UC: upper respiratory tract infections, increased blood creatine phosphokinase, acne, neutropenia, elevated liver enzymes and rash CD: upper respiratory tract infections, anemia, pyrexia, acne, herpes zoster and headache



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Rituxan (rituximab)	Genentech	• RA	 IV infusion only: Administer only by a health care professional 	 IV: 100 mg/10 mL single dose vial 500 mg/50 mL single dose vial 	 Refrigerate vials at 36°F to 46°F (2°C to 8°C) Do not freeze or shake Protect from direct sunlight 	Upper respiratory tract infection, nasopharyngitis, urinary tract infection and bronchitis (other important adverse reactions include infusion-related reactions, serious infections and cardiovascular events)
Ruxience (rituximab-pvvr)	Pfizer	• RA	 IV infusion only: Administer only by a health care professional 	IV: • 100 mg/10 mL single dose vial • 500 mg/50 mL single dose vial	 Refrigerate vials at 36°F to 46°F (2°C to 8°C) Do not freeze or shake Protect from direct sunlight 	Upper respiratory tract infection, nasopharyngitis, urinary tract infection and bronchitis (other important adverse reactions include infusion-related reactions, serious infections and cardiovascular events)
Saphnelo (anifrolumab-fnia)	AstraZeneca	• SLE	IV Infusion: • Infused by a health care professional	IV: • 300 mg/2 mL single dose vial	 Store in a refrigerator at 36°F to 46°F (2°C to 8°C) Store in the original carton to protect from light Do not freeze Do not shake 	Nasopharyngitis, upper respiratory tract infections, bronchitis, infusion related reactions, herpes zoster and cough



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Siliq (brodalumab)	Valeant/Ortho Dermatologics	• PsO	SC injection: • Self-administered	SC: • 210 mg/1.5 mL PFS	 Store refrigerated at 36°F to 46°F (2°C to 8°C) Store in the original carton to protect from light Do not freeze Do not shake 	Arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia and tinea infections
Simlandi (adalimumab-ryvk)	Alvotech/Teva	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	SC: • 40 mg/0.4 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Store in original carton 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash
Simponi ARIA (golimumab)	Janssen	• AS • PJIA (2+) • PsA (2+) • RA	 IV infusion only: Infused by a health care professional 	IV: • 50 mg/4 mL single dose vial	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Do not shake Store in original carton to protect from light 	Upper respiratory tract infection, alanine aminotransferase increased, viral infection, aspartate aminotransferase increased, neutrophil count decreased, bronchitis, hypertension and rash



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Skyrizi (risankizumab-rzaa)	AbbVie	IV/OBI: • CD • UC SC: • PsA • PsO	 IV infusion: Infused by a health care professional SC injection: Self-administered 	IV: • 600 mg/10 mL single dose vial SC: • 360 mg/2.4 mL OBI • 150 mg/mL PEN • 150 mg/mL PFS	 Store in a refrigerator at 36°F to 46° F (2°C to 8°C) Do not freeze Do not shake Store in the original cartons to protect from light 	 PsO and PsA: upper respiratory infections, headache, fatigue, injection site reactions and tinea infections CD: Induction: upper respiratory infections, headache, and arthralgia. Maintenance: arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy and urinary tract infection
Sotyktu (deucravacitinib)	Bristol Meyers Squibb	• PsO	Oral	Oral: • 6 mg tablets	Store at 68°F to 77°F (20°C to 25°C)	Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Stelara (ustekinumab)	Janssen	• CD • PsA (6+) • PsO (6+) • UC	 IV infusion: Prepared and infused by a health care professional SC injection: Self-administered 	IV: • 130 mg/26 mL single dose vial SC: • 45 mg/0.5 mL PFS • 90 mg/mL PFS • 45 mg/0.5 mL single-dose vial	 Refrigerate 36°F to 46°F (2°C to 8°C) Do not freeze Do not shake Store in original carton to protect from light 	PsO: nasopharyngitis, upper respiratory tract infection, headache and fatigue CD: Induction: vomiting. Maintenance: nasopharyngitis, injection site erythema, vulvovaginal candidiasis/ mycotic infection, bronchitis, pruritus, urinary tract UC: Induction: nasopharyngitis. Maintenance: nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue and nausea
Taltz (ixekizumab)	Eli Lilly	 AS Nr-axSpA PsA PsO (6+) 	SC injection: • Self-administered	SC: • 20 mg/0.25 mL PFS • 40 mg/0.5 mL PFS • 80 mg/mL PEN • 80 mg/mL PFS	 Refrigerate 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light Do not shake 	Injection site reactions, upper respiratory tract infections, nausea and tinea infections



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Tremfya (guselkumab)	Janssen	• PsA • PsO • UC	 SC injection: Self-administered IV infusion: Prepared and infused by a health care professional 	SC: • 100 mg/mL PFS • 100 mg/mL PEN • 200 mg/2 mL PFS • 200 mg/2 mL PEN IV: • 200 mg/20 mL single dose vial	 Refrigerate at 36°F to 46°F (2°C to 8°C) Store in original carton to protect from light Do not freeze Do not shake 	Upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections and herpes simplex infections
Truxima (rituximab-abbs)	Celltrion/Teva	• RA	 IV infusion only: Administer only by a health care professional 	 IV: 100 mg/10 mL single dose vial 500 mg/50 mL single dose vial 	 Refrigerate vials at 36°F to 46°F (2°C to 8°C) Do not freeze or shake Protect from direct sunlight 	Upper respiratory tract infection, nasopharyngitis, urinary tract infection and bronchitis (other important adverse reactions include infusion-related reactions, serious infections and cardiovascular events)
Tyenne (tocilizumab-aazg)	Fresenius Kabi	• GCA • PJIA (2+) • RA • SJIA (2+)	 SC Injection: Self-administered IV infusion: Prepared and infused by a health care professional 	SC: • 162 mg/0.9 mL PFS • 162 mg/0.9 mL PEN IV: • 80 mg/4 mL single dose vial • 200 mg/10 mL single dose vial • 400 mg/20 mL single dose vial	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Store in original packages Protect from light Keep syringes dry 	Upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased alanine aminotransferase (ALT) and injection site reactions



Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Velsipity (etrasimod)	Pfizer	• UC	Oral	Oral: • 2 mg tablet	 Store at room temperature at 68°F to 77°F (20°C to 25°C) 	Headache, elevated liver tests and dizziness
Xeljanz/Xeljanz XR (tofacitinib)	Pfizer	 AS PJIA (2+) PsA RA UC 	Oral	Oral: • Tablets: – 5 mg – 10 mg • XR tablets: – 11 mg – 22 mg • Oral Solution: – 1 mg/mL	 Store at room temperature at 68°F to 77°F (20°C to 25°C) Do not repackage 	RA, PsA, AS and PJIA: upper respiratory tract infection, nasopharyngitis, diarrhea and headache UC: nasopharyngitis, elevated cholesterol levels, headache, upper respiratory tract infection, increased blood creatine phosphokinase, rash, diarrhea and herpes zoster
Yuflyma (adalimumab-aaty)	Celltrion	 AS CD (6+) HS PJIA (2+) PsO PsA RA UC UV 	SC injection: • Self-administered	SC: • 20 mg/0.2 mL PFS • 40 mg/0.4 mL PFS • 40 mg/0.4 mL PEN • 80 mg/0.8 mL PEN	 Refrigerate at 36°F to 46°F (2°C to 8°C) Do not freeze Protect from light 	Infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash



Select FDA-approved AI specialty medications and infusion therapy

Drug name	Manufacturer	FDA- Approved Indication(s)	Route of Administration	Supply Method	Storage	Select Common Adverse Reactions
Zeposia (ozanimod)	Bristol Myers Squibb	•UC	Oral	Oral: • 7 Day starter pack: - 0.23 mg capsules - 0.46 mg capsules • 0.92 mg capsules	 Store at 68°F to 77°F (20°C to 25°C) 	Liver test increased, upper respiratory infection and headache



Visit **cvs.co/ai-list** or scan the QR code to view electronically. For easy access, you can bookmark this page.

FDA (U.S. Food and Drug Administration). SC (Subcutaneous). IV (Intravenous). PFS (Prefilled syringe). OBI (On-body injector).

AA (Alopecia areata). AD (Atopic dermatitis). aGVHD (Acute graft versus host disease). AOSD (Adult-onset Still's Disease). AS (Ankylosing spondylitis). CAPS (Cryopyrin-associated periodic syndrome). CRS (Cytokine release syndrome). COPD (Chronic obstructive pulmonary disease). CRSwNP (Chronic rhinosinusitis with nasal polyposis). DIRA (Deficiency of IL-1–receptor antagonist). EoE (Eosinophilic esophagitis). ERA (Enthesitis-related arthritis). FCAS (Familial cold autoinflammatory syndrome). FMF (Familial Mediterranean fever). GCA (Giant cell arteritis). HIDS/MKD (Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency). HS (Hidradenitis Suppurativa). JIA (Juvenile idiopathic arthritis). LN (Lupus Nephritis). MWS (Muckle-Wells syndrome). NOMID (Neonatal-onset multisystem inflammatory disease). Nr-axSpA (Non-radiographic axial spondyloarthritis). PJIA (Polyarticular Juvenile idiopathic arthritis). PMR (Polymyalgia rheumatica). PN (Prurigo nodularis). PsA (Psoriatic arthritis). PsO (Plaque psoriasis). RA (Rheumatoid arthritis). RP (Recurrent pericarditis). SJIA (Systemic Juvenile idiopathic arthritis). SLE (Systemic lupus erythematosus). SSc-ILD (Systemic scleroisis - Interstitial lung disease). TRAPS (Tumor necrosis factor receptor-associated periodic syndrome). UC (Ulcerative colitis). UV (Uveitis).

The information contained in this communication is provided in summary form. It is not intended for use as the sole basis of clinical treatment, as a substitute for reading the original research, nor as a substitute for the knowledge, skill and judgment of the medical provider. This list is subject to change. CVS Specialty assumes no liability whatsoever for the information provided or for any diagnosis or treatment made as a result of this information. The information noted in this brochure was taken from the manufacturers' prescribing information. It does not contain all information needed to use these products safely and effectively. See the manufacturers' package insert for full prescribing information. CVS Specialty does not provide medical advice and does not recommend a particular treatment or brand. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Specialty.

©2025 CVS Specialty. All rights reserved. 75-25982A 010625